Therapeutic indications
Experience in treating women over 65 years of age is limited.
Lenzetto is prescribed once a day as monotherapy or continuous sequential therapy.
therapy (when combined with progestogen).
The initial dose is one measured dose of spray and is applied once a day to dry and healthy skin of the forearm. Depending on the clinical response, the daily dose can be increased to two doses of spray applied daily to the forearm. Dose increases should be based on the severity of menopausal symptoms and should be made after at least 4 weeks of continuous treatment with Lenzetto. The maximum daily dose is 3 spray doses (4.59 mg/day) applied to the forearm. Dose increases must be approved by your physician. Patients who find it difficult to apply the prescribed dose to non-overlapping areas of one forearm may also apply Lenzetto to the corresponding area of the other forearm or to the inner thigh.
To begin and continue treatment of postmenopausal symptoms, the lowest effective dose should be used for the shortest possible time (see also section “Contraindications”).
If the severity of menopausal symptoms does not decrease after increasing the dose, the patient should be transferred back to the previous dose.
It should be checked regularly according to clinical need (for example, at intervals of 3 to 6 months).
patients’ condition and determine whether treatment is necessary (see section 4.4).
If estrogen is prescribed to a postmenopausal woman with a uterus, the woman should also be given a progestogen approved as an adjunctive therapy to estrogen therapy to reduce the risk of endometrial cancer. Only progestogens approved as an adjunctive therapy to therapy should be prescribed estrogens.
Women with a uterus
In women with an intact uterus, the drug should be combined with a progestogen approved as an adjunctive therapy to estrogen therapy in a continuous sequential dosing regimen: estrogen is administered continuously. Progestagen is taken sequentially for at least 12-14 days a day every monthly/28-day cycle.
Patients who have not previously received treatment or are switching from another HRT (cyclic, sequential or continuous combination) should be instructed on how to begin treatment. Intermenstrual bleeding may occur when estrogen is combined with a progestogen. The next 28-day cycle begins without interruption in the use of the drug.
Women after hysterectomy (without uterus)
In the absence of a previous diagnosis of endometriosis, it is not recommended to add progestogen to women.
after hysterectomy.
Overweight and obese women
There is limited evidence that the rate and amount of absorption of Lenzetto may be reduced in overweight and obese women. Dose adjustment of Lenzetto may be necessary during treatment. Dose changes must be approved by your physician.
